PL2275108T3 - Preparat farmaceutyczny zawierający inhibitor dpp-iv i inny terapeutyczny środek na cukrzycę w postaci stosowanej równocześnie lub w postaci połączonej - Google Patents

Preparat farmaceutyczny zawierający inhibitor dpp-iv i inny terapeutyczny środek na cukrzycę w postaci stosowanej równocześnie lub w postaci połączonej

Info

Publication number
PL2275108T3
PL2275108T3 PL09746569T PL09746569T PL2275108T3 PL 2275108 T3 PL2275108 T3 PL 2275108T3 PL 09746569 T PL09746569 T PL 09746569T PL 09746569 T PL09746569 T PL 09746569T PL 2275108 T3 PL2275108 T3 PL 2275108T3
Authority
PL
Poland
Prior art keywords
dpp
concomitant
inhibitor
therapeutic agent
pharmaceutical preparation
Prior art date
Application number
PL09746569T
Other languages
English (en)
Inventor
Moritaka Goto
Satoko Yamashita
Keizo Nakaya
Tetsushi Tomoguri
Tsutomu Ishida
Masahiro Fuchigami
Original Assignee
Sanwa Kagaku Kenkyusho Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanwa Kagaku Kenkyusho Co filed Critical Sanwa Kagaku Kenkyusho Co
Publication of PL2275108T3 publication Critical patent/PL2275108T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL09746569T 2008-05-14 2009-05-12 Preparat farmaceutyczny zawierający inhibitor dpp-iv i inny terapeutyczny środek na cukrzycę w postaci stosowanej równocześnie lub w postaci połączonej PL2275108T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008127480 2008-05-14
EP09746569.4A EP2275108B1 (en) 2008-05-14 2009-05-12 Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form
PCT/JP2009/058803 WO2009139362A1 (ja) 2008-05-14 2009-05-12 Dpp-iv阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬

Publications (1)

Publication Number Publication Date
PL2275108T3 true PL2275108T3 (pl) 2015-01-30

Family

ID=41318729

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09746569T PL2275108T3 (pl) 2008-05-14 2009-05-12 Preparat farmaceutyczny zawierający inhibitor dpp-iv i inny terapeutyczny środek na cukrzycę w postaci stosowanej równocześnie lub w postaci połączonej

Country Status (15)

Country Link
US (1) US8633199B2 (pl)
EP (1) EP2275108B1 (pl)
JP (1) JP4643760B2 (pl)
KR (1) KR101607081B1 (pl)
CN (1) CN102026641A (pl)
AU (1) AU2009247251B2 (pl)
BR (1) BRPI0912607A2 (pl)
CA (1) CA2724133C (pl)
DK (1) DK2275108T3 (pl)
ES (1) ES2507491T3 (pl)
MX (1) MX2010012245A (pl)
PL (1) PL2275108T3 (pl)
PT (1) PT2275108E (pl)
RU (1) RU2523552C2 (pl)
WO (1) WO2009139362A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
TW201412745A (zh) * 2012-08-28 2014-04-01 Sanwa Kagaku Kenkyusho Co Ｎ－［２－（｛２－［（２Ｓ）－２－氰基吡咯啶－１－基］－２－側氧乙基｝胺基）－２－甲基丙基］－２－甲基吡唑并［１，５－ａ］嘧啶－６－甲醯胺之結晶
KR20150059720A (ko) * 2012-09-27 2015-06-02 가부시키가이샤산와카가쿠켄큐쇼 아나글립틴 함유 제제
WO2014051025A1 (ja) * 2012-09-27 2014-04-03 株式会社 三和化学研究所 アナグリプチン含有固形製剤
WO2014051024A1 (ja) * 2012-09-27 2014-04-03 株式会社 三和化学研究所 アナグリプチン含有医薬組成物
TWI500613B (zh) 2012-10-17 2015-09-21 Cadila Healthcare Ltd 新穎之雜環化合物
WO2014065427A1 (ja) * 2012-10-26 2014-05-01 株式会社 三和化学研究所 アナグリプチン含有固形製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076811A1 (en) 2000-01-21 2008-03-27 Bork Balkan Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
ATE385421T1 (de) 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
AU2004207731B2 (en) * 2003-01-31 2009-08-13 Sanwa Kagaku Kenkyusho Co., Ltd. Compound inhibiting dipeptidyl peptidase iv
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
BRPI0611074A2 (pt) 2005-06-03 2010-11-23 Mitsubishi Tanabe Pharma Corp agentes farmacêuticos concomitantes e uso dos mesmos
KR20080081354A (ko) 2005-12-28 2008-09-09 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료제
US7478621B2 (en) * 2006-04-11 2009-01-20 Zf Friedrichshafen Ag Method of compensating for engine speed overshoot

Also Published As

Publication number Publication date
US20110071166A1 (en) 2011-03-24
CA2724133C (en) 2016-07-12
DK2275108T3 (da) 2014-09-08
CA2724133A1 (en) 2009-11-19
AU2009247251A2 (en) 2011-02-10
ES2507491T3 (es) 2014-10-15
JP4643760B2 (ja) 2011-03-02
PT2275108E (pt) 2014-09-30
RU2523552C2 (ru) 2014-07-20
MX2010012245A (es) 2011-04-11
WO2009139362A1 (ja) 2009-11-19
RU2010143817A (ru) 2012-06-20
BRPI0912607A2 (pt) 2019-09-17
AU2009247251B2 (en) 2013-07-18
EP2275108B1 (en) 2014-07-09
KR101607081B1 (ko) 2016-03-29
EP2275108A4 (en) 2011-04-27
CN102026641A (zh) 2011-04-20
AU2009247251A1 (en) 2009-11-19
JPWO2009139362A1 (ja) 2011-09-22
KR20110016889A (ko) 2011-02-18
EP2275108A1 (en) 2011-01-19
US8633199B2 (en) 2014-01-21

Similar Documents

Publication Publication Date Title
EP2275108A4 (en) PHARMACEUTICAL PREPARATION COMPRISING A DPP-IV INHIBITOR AND OTHER DIABETES THERAPEUTIC AGENTS IN CONCOMITANT OR COMBINED FORM
IL275854A (en) Pharmaceutical composition and its administration
ZA201206062B (en) Aminotetraline derivatives,pharmaceutical compositions containing them,and their use in therapy
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
IL209267A (en) Combinations containing methotrexate and dhodh inhibitors and their use in the preparation of the drug
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
IL218169A (en) Quinazoline compounds and their pharmaceutical compositions containing them for use in therapy
HU0700828D0 (en) Transdermal pharmaceutical compositions containing tol perisone alone and in combination
IL206690A0 (en) Protein kinase inhibitors and their use in the preparation of medicaments
IL208463A (en) 2-Trotocyclic-Pirol compounds combined, pharmaceutical preparations containing them and their use in the prevention or treatment of diabetes or obesity
GB0523576D0 (en) Drug composition and its use in therapy
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
GB0921803D0 (en) Drug composition and its use in therapy
EP2322207A4 (en) OXYGEN TRANSMITTING BLOOD SUBSTITUTE AND PHARMACEUTICAL COMPOSITION (VARIANTS)
GB0919889D0 (en) Drug composition and its use in therapy
ZA201104710B (en) Pharmaceutical dispenser and use thereof
PT2117519E (pt) Composição farmaceutica compreendendo tramadol e cetoprofeno
GB0921805D0 (en) Drug composition and its use in therapy
GB0919893D0 (en) Drug composition and its use in therapy
GB0910375D0 (en) Drug composition and its use in therapy
EP2018178A4 (en) ADMINISTRATION OF AN AGONIST-ANTAGONIST COMPLEX TO PATIENTS WITH OPIOID DEPENDENCE
PL2236145T3 (pl) Kompozycja farmaceutyczna i lek złożony
GB0909352D0 (en) Drug composition and its use in therapy